<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931524</url>
  </required_header>
  <id_info>
    <org_study_id>14C-ANG3777-HV4-102</org_study_id>
    <nct_id>NCT04931524</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777</brief_title>
  <official_title>An Open Label, Single-Dose Study to Assess the Mass Balance Recovery, Metabolism and Excretion of [14C] ANG 3777 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angion Biomedica Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Angion Biomedica Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the mass balance recovery and metabolic profiling and&#xD;
      identification of 14C-ANG-3777 administered as a single IV dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, non-randomized study. Blinding is not required.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity (TR) in all excreta urine: CumAe and Cum%Ae</measure>
    <time_frame>Day 1 to Day 8 (or Day 1 to Day 12)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity (TR) in all excreta faeces: CumAe and Cum%Ae</measure>
    <time_frame>Day 1 to Day 8 (or Day 1 to Day 12)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of plasma samples for metabolite profiling, structural identification, and quantification analysis</measure>
    <time_frame>Day 1 to Day 8, or up to Day 12 (except for metabolite profiling up to Day 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of urine samples for metabolite profiling, structural identification, and quantification analysis</measure>
    <time_frame>Day 1 to Day 8, or up to Day 12 (except for metabolite profiling up to Day 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of faeces samples for metabolite profiling, structural identification, and quantification analysis</measure>
    <time_frame>Day 1 to Day 8, or up to Day 12 (except for metabolite profiling up to Day 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of routes of elimination of [14C]-ANG-3777 by Ae, %Ae, CumAe and Cum%Ae by interval</measure>
    <time_frame>Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of rates of elimination of [14C]-ANG-3777 by Ae, %Ae, CumAe and Cum%Ae by interval</measure>
    <time_frame>Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of parent ANG-3777 in plasma including but not limited to: Tmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of parent ANG-3777 in plasma including but not limited to: Cmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of parent ANG-3777 in plasma including but not limited to: AUC(0-last) and AUC(0-inf)</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of parent ANG-3777 in urine including but not limited to: Tmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of parent ANG-3777 in urine including but not limited to: Cmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of parent ANG-3777 in urine including but not limited to: AUC(0-last), and AUC(0-inf)</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of parent ANG-3777 in faeces including but not limited to: Tmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of parent ANG-3777 in faeces including but not limited to: Cmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of parent ANG-3777 in faeces including but not limited to: AUC(0-last), and AUC(0-inf)</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of TR in plasma including but not limited to: Tmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of TR in plasma including but not limited to: Cmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of TR in plasma including but not limited to: AUC(0-last), and AUC(0-inf)</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of TR in urine including but not limited to: Tmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of TR in urine including but not limited to: Cmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of TR in urine including but not limited to: AUC(0-last), and AUC(0-inf)</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of TR in faeces including but not limited to: Tmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of TR in faeces including but not limited to: Cmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the appropriate PK parameters of TR in faeces including but not limited to: AUC(0-last), and AUC(0-inf)</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of whole blood:plasma concentration ratios for TR</measure>
    <time_frame>Plasma from Day 1 to Day 8; whole blood up to Day 2</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>carbon-14-[14C]-ANG-3777</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered IV as a single dose over 30 minutes on the morning of Day 1 following an 8 hour overnight fast and remain in the clinical unit until up to 168 hours after dosing (to Day 8). If mass balance criteria have not been met on Day 8, the clinical unit residency may be extended up to an additional 96 hours (to Day 12).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbon-14-[14C]-ANG-3777</intervention_name>
    <description>Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted</description>
    <arm_group_label>carbon-14-[14C]-ANG-3777</arm_group_label>
    <other_name>Hepatocyte growth factor mimetic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males&#xD;
&#xD;
          2. Aged 30 to 65 years inclusive at the time of signing informed consent&#xD;
&#xD;
          3. Body mass index (BMI) of 18.0 to 32.0 kg/m2 and weighing 50 to 120 kg as measured at&#xD;
             screening&#xD;
&#xD;
          4. Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          5. Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per&#xD;
             day)&#xD;
&#xD;
          6. Must provide written informed consent&#xD;
&#xD;
          7. Must agree to adhere to the contraception requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have received any IMP in a clinical research study within the 90 days&#xD;
             prior to Day 1&#xD;
&#xD;
          2. Subjects who are, or are immediate family members of, a study site or sponsor employee&#xD;
&#xD;
          3. Evidence of current SARS-CoV-2 infection.&#xD;
&#xD;
          4. History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          5. Regular alcohol consumption &gt;21 units per week (1 unit = ½ pint beer, or a 25 mL shot&#xD;
             of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)&#xD;
&#xD;
          6. A confirmed positive alcohol breath test at screening or admission&#xD;
&#xD;
          7. Current smokers and those who have smoked within the last 12 months. A confirmed&#xD;
             breath carbon monoxide reading of greater than 10 ppm at screening or admission&#xD;
&#xD;
          8. Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharan Sidhu, MBChB, BAO, MRCS, MFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences - Nottingham, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chantal Swiszcz</last_name>
    <phone>857-378-4175</phone>
    <email>cswiszcz@angion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Robledo</last_name>
    <phone>857-378-4173</phone>
    <email>mrobledo@angion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharan Sidhu, MBChB, BAO, MRCS, MFPM</last_name>
      <phone>+44 (0)115 974 9000</phone>
      <email>sharan.sidhu@quotientsciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

